Clinical trials: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Long-lasting Bicarbonate-Sulfate-Calcium-Magnesium Water Intake on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Outcome
Background: Fonte Essenziale®, a mineral water rich in bicarbonate, sulphate, calcium, and magnesium, has shown potential in modulating the gut-liver axis and microbiota in hepatic steatosis.
- Trial name
- FonteESSEMASLD (NCT07211113)
- Testing
- Fonte Essenziale® mineral water
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- University of Campania Luigi Vanvitelli
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
This is a 3-month, single-center, prospective, randomized, parallel-controlled, open-label trial investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes…
- Trial name
- MDEITM (NCT07778719)
- Testing
- Metformin + Dapagliflozin, Metformin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- The 95th Hospital of Putian，Putian, Fujian, China
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- NCT06493253
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- United States
- Volunteers
- 1,519 people
- Sponsor
- PharmaNest, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease
Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation
Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2020, is an improved diagnostic standard evolved from non-alcoholic fatty liver disease (NAFLD), emphasizing the correlation between hepatic steatosis…
- Trial name
- MASLD (NCT07488975)
- Testing
- Pasteurized Akkermansia muciniphila LWHK0003_low dose, Pasteurized Akkermansia muciniphila LWHK0003_medium dose, Pasteurized Akkermansia muciniphila LWHK0003_high dose
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Leeuwenhoek Laboratories Co. Ltd.
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Liver Cirrhosis
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant…
- Trial name
- PROMISE (NCT06461208)
- Testing
- Encapsulated FMT
- Where
- 23 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College London
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A study for evaluating the improvement effect on Metabolic dysfunction-associated steatotic liver disease (MASLD) of probiotics Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the…
- Trial name
- NCT04555434
- Testing
- Probiotics
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.
- Trial name
- NCT06218589
- Testing
- Velacur, MRI, Blood sample collection for biomarkers
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MetALD (MASLD and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- MAIL-NIT (NCT06986447)
- Where
- 8 sites in United States
- Volunteers
- 1,689 people
- Sponsor
- HRI-MAIL-NIT
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 25 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Fatty Liver
Alpha-Glutathione-S-Transferase (AlphaGST) and MARINA Index in Metabolic-Dysfunction-Associated-Steatotic-Liver-Disease (MASLD)
AlphaGST represents a liver enzyme whose serologic levels progressively increase in alcoholic and viral chronic hepatitis according to the worsening of liver fibrosis.
- Trial name
- NCT05804955
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- University of Campania Luigi Vanvitelli
Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Prognostic Model for MASLD Related Cirrhosis
This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months.
- Trial name
- NCT07082751
- Testing
- Lifestyle Guidance
- Where
- 9 sites in China
- Volunteers
- 228 people
- Sponsor
- Beijing Friendship Hospital
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH